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Introduction: Chemotherapy in addition to surgery improves outcomes in
gastro-oesophageal cancer. Both the OEO2 (neoadjuvant) and MAGIC
(peri-operative) trials showed statistically significant improvements in overall survival
though only 55% of patients in the MAGIC trial received post-operative treatment. We
investigated whether more neoadjuvant chemotherapy (4 cycles epirubicin/cisplatin
/capecitabine (ECX)) compared to a standard approach (2 cycles of cisplatin/
5-fluorouracil) would improve outcomes.
Methods: A multi-centre, randomised, phase III trial comparing 2 cycles of CF with 4
cycles of ECX followed by oesophagectomy with 2-field lymphadenectomy for lower
oesophageal and junctional (Types I and II) adenocarcinoma. Primary outcome was
overall survival (OS); 842 patients (677 deaths) would detect an increase in 3-year
survival from 30% to 38% (or 37%) with 82% (or 70%) power with 2α = 5%. Deaths
accrued more slowly than anticipated but the Independent Data Monitoring
Committee considered the data sufficiently robust for release. Secondary outcomes
include disease-free (DFS) and progression-free survival (PFS), pathological R0
resection rate, Mandard grade and quality of life (QoL).
Results: From 2005-2011, 897 patients (451 CF, 446 ECX) from 72 UK centres were
randomly allocated (1:1). Baseline characteristics were similar between the groups
(overall, male 90%, median age 62 (IQR 56-67), staging included PET 60%, T3 N0
22%, T3 N1 65%). 96% CF received 2 cycles, 89% ECX > 3 cycles. Grade 3/4 toxicity
was lower with CF (30% v 47% p < 0.001). Of those patients having a resection R0 rates
were CF 60%, ECX 66% with a Mandard grade ≤3 achieved in CF 15% v ECX 32%
with 3% and 11% achieving complete response. Post-operative complications were
similar (CF 57%, ECX 62%) as were deaths at 30 (CF 2%, ECX 2%) and 90 days
post-surgery (CF 4%, ECX 5%). PFS and DFS favoured ECX, hazard ratio (HR, 95%
CI) PFS 0.86 (0.74-1.01), DFS 0.88 (0.75-1.03). HR for OS was 0.92 (0.79-1.08,
p = 0.3017) based on 315 CF and 298 ECX deaths, with similar 3 year survival rates CF
39% (35-44%) vs ECX 42% (37-46%). Exploratory subgroup analyses suggested that N0
patients may benefit from ECX, HR for OS was 0.68 (0.47-0.97). There were no
clinically important differences in QoL (global QoL and oesophageal cancer specific
domains from the EORTC QLQ-C30 and QLQ-OES18 questionnaires), either
pre-operatively or 3-months post-operatively.
Conclusion: There is some evidence of a benefit from the prolonged ECX regimen,
in terms of PFS, DFS and tumour regression at resection, but this does not
translate into a survival benefit. Ongoing translational work is aimed at identifying
subsets of patients that might benefit from the triplet anthracycline containing
regimen.
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